an overall pooled sensitivity and specificity on patients level of 82% (59% to 94%) and 88% (80% to 95%). In the low risk group (five studies) these values were 75% (39% to 93%) and 91% (77% to 97%) respectively.
Introduction
In 2007 the American Cancer Society indicated that prostate cancer is the most commonly diagnosed cancer in the US and with an estimated 27'050 prostate cancer related deaths, the second leading cause of cancer related fatality [1] . This is described in a more meaningful way by Walsh [2] , who wrote that approximately one out of six men in the USA received a diagnosis of prostate cancer in his lifetime, and one out of 34 died from it. Current statistics show that prostate cancer incidence rates are decreasing since 1992 after reaching a peak in the mid 90ties due to the implementation of the PSA screening in the late 80ties. [3] Whether this is a sustained decrease is questionable. Data on demographic changes clearly show that the population of the developed world is ageing rapidly. For example Yancik and colleagues predicted a doubling of the population at the age of 65 years or older by the year 2030 in the USA [4] . Since almost two third of new prostate cancer cases occur in the elderly it can be expected that prostate cancer incidence will rise again. British researchers predict that cancers of the prostate gland could overtake lung cancer as the most common form of the disease in
Britain within 20 years. [5] Arguably the continuing increase in prostate cancer detection may be attributable to increased screening through prostate-specific antigen (PSA) testing. However, both in screening and diagnostic work-up PSA appear to be of low accuracy: using a threshold of <4ng/ml showed a prevalence of only 15% of prostate cancer [6] and a threshold between 4
and 10ng/ml a prevalence of only 33% of prostate cancer [7] .Moreover, rule-in diagnosis with transrectal needle biopsy has been shown to be remarkably inaccurate [8] [9] [10] with a cancer missing rate of up to 20% using a traditional sextant biopsy schema; indeed, an approach with a ten to twelve prostate needle biopsy schema leads to a 30% improvement in cancer detecting [11] . Over the last decade, imaging technologies, such as combined magnetic resonance imaging (MRI) and magnetic resonance spectroscopy imaging (MRSI) have shown promise for improving the detection and characterization of prostate cancer. However, these technologies have not yet entered into routine clinical care and their clinical role remains debated.
The aim of this systematic review and meta-analysis was to establish the current role of combined MRI and MRSI in the diagnosis of prostate cancer and to explore risk profiles with the highest benefit.
Evidence Acquisition
We used methods recommended by the Cochrane methods group for the systematic review of screening and diagnostic tests [12] .
Identification of studies
We searched MEDLINE, Cochrane Library and EMBASE to identify diagnostic studies evaluating the accuracy of combined MRI and MRSI in the diagnosis of prostate cancer. Last search was performed in August 2008. Checking the reference lists of included studies and contacting experts in the field complemented electronic searches. The detailed search strategy for Medline can be found in the Appendix.
Study selection
We included studies if they compared MRI in combination with MRSI results and potentially other imaging methods (e.g. diffusion and contrast enhanced MRI) with the results of prostate biopsies or prostatectomy specimens in patients with either previously diagnosed or suspected prostate cancer. The minimum requirement for inclusion was enough information to fill the two-by-two table. All papers considered potentially eligible by one of the two observers were ordered and a checklist was used to determine final eligibility.
Disagreements about inclusion or exclusion were resolved by consensus.
We initially included thirty-one studies [8, . For details see figure 1. contained two separate populations (with and without previous hormone treatment). We treated them as two separate studies. We excluded three further studies [43] [44] [45] because they used a diagnostic case-control design which is prone to show over optimistic accuracy measures [46] Data extraction and assessment of methodological quality
The methodological quality of all eligible papers was assessed based on published recommendations [46] . Quality assessment involved scrutinizing the methods of data collection and patient selection, and descriptions of the test and reference standard. Studies were considered to be prospective if the study protocol preceded data collection. Blinding was fulfilled if the person making the definite imaging diagnosis did not know the results of the pathologic examination. One reviewer assessed papers and extracted data using a standardized form (the data extraction form is available on request). This reviewer contacted a second reviewer if an item could not be clearly addressed. Decisions were based on a consensus between the two reviewers. Papers published in languages other than English, German or French were translated.
Risk stratification
We a priori defined a set of five parameters (men's age, PSA, Gleason-score, number of previous negative prostate biopsies and rate or dimension of detected cancer) to classify study populations into low or high risk groups for clinically relevant prostate cancer. For example, we classified patients into the low risk group if PSA values were low (<10 ng/ml) or if previous needle biopsies had been negative. We classified men older than 65 years presenting with a Gleason Score higher than six and larger tumours (diameter > 5mm) as determined in the prostatectomy specimen or a high positive core rate (>10%) as high risk.
The classification was performed separately by two urologists and discrepancies -often due to missing data especially concerning tumour dimensions or positive core rate -were discussed and resolved by consensus.
Index test
For each study we extracted details about the MR scanner field strength, use of an endorectal or superficial body coil, spectroscopic acquisition parameters and metabolic cut-off values for a positive result. In three studies that assessed different cut off values we chose the highest available (> 3 SD higher than normal) to optimize the false positive rate. If studies contained test performance results for experienced and inexperienced spectroscopy readers separately, we only used the data of the experienced examiners. Two urologists separately classified the patient cohorts based on the studies' inclusion criteria. Discrepancies were discussed and resolved by consensus.
Sensitivity, specificity and accuracy calculation
We calculated the sensitivity and specificity of the combined positive or negative MRI/MRSI result on patient level within the seven studies including patients with cancer suspicion. In the remaining nine studies (including ten populations) we calculated sensitivity, specificity of the combined positive or negative MRI/MRSI result not on patient level but on a prostate subpart level. Different to studies assessing test performance on patient level these studies match the cancer status (present/absent) of a prostate subpart with the test result (positive/negative) of that corresponding part of prostate.
Statistical analysis
For each study, we constructed a two-by-two contingency table consisting of truepositive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) results. For analysis, we called a result a true positive if both MRI and MRSI were concordant and were in agreement with the pathological findings. We calculated sensitivity as TP/(TP + FN) and specificity as TN/(FP + TN). We plotted results from individual studies in ROC space and estimated summary ROC curves using a unified model for meta-analysis of diagnostic test accuracy studies [47] . We also indicated on the ROC-figures the confidence and prediction regions. The advantage of doing this is that it provides estimates of average sensitivity and specificity across studies, and can be used to provide a 95 percent confidence region for this summary point and prediction regions within which we expect the sensitivity and specificity of 95 percent of future studies to lie. We performed stratified analyses for studies reporting on cancer status in terms of proven and suspected cancer at the time of the MRI/MRSI exam. In these subgroups we also assessed differences in sensitivity and specificity between low and high risk patients in respect to clinically relevant cancer. We pooled results if at least four studies per stratum were available. Following recent recommendations we refrained from pooling positive and negative likelihood ratios because these are sensible parameters to analyze statistically in a meta-analysis. [48] Instead, we calculated the likelihood ratios from the estimated pooled sensitivities and specificities. All analyses were done using the Stata statistical software package (Version 9.2, College Station, Texas, USA).
Evidence Synthesis
Identification of studies and study quality Figure 1 summarizes the process of identifying and selecting studies. Thirty-one studies met our primary inclusion criteria. Study characteristics are shown in Table 1 .
Study Quality
Twelve out of thirty-one reports had a prospective design [8, [8, 16, 26, 37, 38, 40, 50] . For imaging interpretation, these studies used the biopsy as the standard of reference without correlation to a specific region of the prostate. For details see Table 1 .
Pooled sensitivity and specificity Table 2 shows for each study population the number of true positives, false positives, false negatives and true negatives, as well as sensitivity and specificity. The accuracy parameters in studies assessing patients with suspected cancer are based on patient level and in studies assessing patients with previously diagnosed cancer on classification of prostate subpart level.
Confirmed versus suspected prostate cancer at the time of imaging
The pooled mean sensitivity of ten two-by-two tables investigating men with confirmed cancer using a cancer threshold value for MRSI of > 3 SD deviations from normal (Choline + Creatinine)/Citrate, was 68% (95% CI; 56% to 78%) and specificity was 85% (95% CI; 78% to 90%). (Figure 3) The corresponding positive and negative likelihood ratios were 4.5 and 0.37. The pooled sensitivity and specificity of five studies investigating men with suspected prostate cancer was 82% (95% CI; 59% to 94%) and 88% (95% CI; 80% to 95%). (Figure 4) The corresponding positive and negative likelihood ratios were 6.8 and 0.15.
Risk stratification in the confirmed cancer group
For the confirmed prostate cancer studies we performed a risk-stratification for patient cohorts with low and high pretest probability of having clinical relevant cancer. (Figures 5 and 6 ).
Risk stratification in the suspected cancer group
We were unable to calculate pooled estimates for the high risk group. In the low risk group [8, 15, 37, 38, 40] sensitivity was 75% (39% to 93%) and specificity was 91% (77% to 97%)
respectively. (Figure 7) Discussion This is the first meta-analysis examining the combined diagnostic value of Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy imaging (MRSI) in the workup of prostate cancer patients. We found limited evidence indicating a potential role of this technique in the future. At this stage clinical implications of our results remain limited due to several reasons. Studies tended to be of limited size, applied different methods and investigated a broad spectrum of patients. Moreover, study quality and reporting was limited.
For example, only seven studies reported that radiologists were blinded for pathological information and only few gave a detailed description of clinically relevant information of enrolled patients such as PSA levels and Gleason Scores. Finally, we found substantial variation in the way spectroscopy findings were used for the identification of prostate cancer indicating a lack of consensus regarding diagnostic criteria and thresholds.
Our findings in context of existing literature
We found two systematic [51, 52] and two non-systematic reviews [53, 54] . In 2002
Engelbrecht and colleagues [52] made a first systematic attempt to summarize the clinical value of the MRI in local staging of prostate cancer. The study also assessed the value of MRSI in that field but failed to perform a meta-analysis due to the limited number of available studies. Their search was limited to the year 2000 and they only searched two databases. Moreover, all but three studies assessing the diagnostic value of MRSI in combination with MRI were published after the year 2000. The other meta-analysis investigated the diagnostic value of MR spectroscopy in the diagnosis of prostate cancer [51] but not the value of combined MRI/MRSI.
Strength and limitations
Our review was based on thorough literature searches and careful data extraction, and included assessments of the methodological quality of diagnostic test accuracy studies. This is the first study performing a meta-analysis in this diagnostic field. We modelled sensitivity and specificity simultaneously applying a novel and valid meta-analytic method, which incorporates both within and between study variance [47] . In addition we performed stratified analyses to examine variability of results between subgroups of patients. Reporting of salient clinical features was suboptimal in some of the studies. This could have introduced bias in our results. A further limitation is that many studies used prostate needle biopsy cores as the reference method which is considered to be a poor gold standard due to the high missing rate.
Moreover nine studies matched the cancer status (present/absent) of a prostate subpart with the test result (positive/negative) of that corresponding part of prostate to calculate sensitivity and specificity assuming that these figures represent a fair proxy for test performance in clinical practice. Also, due to the fact that some studies excluded substantial numbers of patients or prostate subparts due to poor imaging quality we cannot fully rule-out selection bias in these studies. Although we aimed at quantifying the additional value of combined MRI / MRSI over MRI technology alone the paucity of such data in our set of studies impeded us from doing a solid analysis. Finally, we performed this systematic review in a rapidly evolving field of research and we cannot exclude that relevant reports appeared while completing this study.
Implication for research
We believe that future studies of the diagnostic value of new MR imaging technologies should include recent methodological recommendations for studies evaluating diagnostic tests [55] . Researchers should be encouraged to agree on data acquisition protocols and data analysis algorithms to increase the comparability of studies. Careful reporting of those methods will facilitate the evaluation to the extent that the results are applicable to other clinical settings. For example, in the studies included in this meta-analysis the pathologic standard of reference for cancer presence varied substantially leading to variability in test performance measures [46] .
Implications for practice
Based on the results of our study we think that it is too early to call for broad application of this method in clinical practice. We speculate that further improvement of the technology will increase its role in the future. For example higher field strengths will lead to a better spatial resolution and the combination of existing techniques with diffusion weighted imaging and dynamic contrast enhanced MRI could provide additional functional information concerning the presence and stage of prostate cancer. A further challenge needing resolution relates to the clinical circumstances for which MRI/MRSI is most useful. Can MRI/MRSI play a role in identifying cancer in men with a rising PSA but negative prior biopsies or can it help confirming that a biopsy procedure has not missed a clinically significant tumour?
Conclusion
A limited number of small studies suggest that magnetic resonance imaging combined with magnetic resonance spectroscopy could be a rule-in test for low risk patients. This finding needs further confirmation in larger studies and. cost-effectiveness needs to be established. Articles excluded -lack of data to construct 2x2 table n = 23 -lack of involvement of MRSI n = 6 -not diagnostic approach (T2 vs T3) n = 3 -case-control design on subpart of prostate level n = 3
Studies excluded due to lack of original data (reviews, comments)
Articles 
